Annovis Bio exceeded enrollment targets for its Phase 3 trial of buntanetap, recruiting 850 patients against a goal of 760 for early Alzheimer's disease. The achievement demonstrates patient demand for novel therapeutics, though the drug's efficacy and regulatory approval remain unproven and contingent on data expected in early 2027.
Key Points
- Exceeded enrollment by 90 patients despite strict biomarker-based entry criteria
- Buntanetap targets multiple pathological proteins across Alzheimer's and Parkinson's
- Cash runway tight; quarterly net loss of $14.8 million despite milestone
Longevity Analysis
Successful trial enrollment reflects genuine clinical need for interventions addressing neurodegeneration beyond single-target approaches. Buntanetap's design—modulating amyloid, tau, and alpha-synuclein simultaneously—represents a shift toward multi-pathway strategies that acknowledge how protein misfolding, immune activation, and cellular stress interconnect in neurodegenerative disease. The ability to recruit patients based on objective biomarkers rather than symptom alone signals an important maturation in how we identify and stage disease. However, enrollment success is distinct from efficacy; the 18-month study will determine whether reducing multiple pathological drivers translates to measurable cognitive preservation, and whether the company's financial constraints allow completion of long-term follow-up needed to assess disease trajectory modification.
Original published by Longevity.Technology, by Eleanor Garth.